MEHRAN BHATTI, CEng, CPSM
I increase the valuation of Cell & Gene Therapy (CGT) and Advanced Therapy organizations through COGS, reliability, and locked material supply strategy.
I blend 8 years of industry experience with the rigour of consulting, developed across four years at Accenture.
of FDA Complete Response Letters cite quality or manufacturing deficiencies.
in lost revenue per day of delay.
NDA programs end entirely due to preventable manufacturing and supply chain causes
If you are a Commercial Biotech
Is your commercial supply chain losing margin on cost while reliability is under pressure, while your pipeline is making decisions that will lock in the next set of supply chain problems?
If you are a Pre-Commercial Biotech
Are you 18 to 24 months from launch without a supply chain function in place?
You need the function built correctly before your permanent head steps into it, or someone who can act as that head while you hire. Either way, the window to make the right decisions is closing.
If you are a CDMO
CDMO sites contribute to up to 40% of CMC-related CRLs. Are your supply chain gaps contributing to sponsor attrition and lost mandates?
The Approach
The Approach
Already know this is your problem? Let us talk.
Where The Value Is
Up to
COGS
Reduction
Procurement and external manufacturing optimisation potential.
Up to
Material Supply
Locked
Of material supply at risk without early SC involvement.
Over
Supply
Reliability
Industry OTIF benchmark.
*by percent spend
Delivered at CARVYKTI
Designed and led the external supply network across 10+ CDMOs and four regulatory jurisdictions through Phase 2 to on-time commercial launch during COVID. Zero critical supply failures across a $40M supply base.
Johnson & Johnson · Advanced Therapies
White Paper
The 9 Year Supply Chain Gap in Drug Development
74% of FDA Complete Response Letters cite quality or manufacturing deficiencies. The decisions that drive those outcomes were made years earlier, without supply chain input.
Selected Mandates
Johnson & Johnson · Advanced Therapies
Advanced Therapies Supply Chain & External Manufacturing — CARVYKTI
CARVYKTI is the first CAR-T approved in multiple myeloma. I led the supply chain through Phase 2 to on-time commercial launch during COVID, across a $40M+ supply base and 10+ CDMOs. Zero critical supply failures at launch. Governance model designed and embedded across Quality, Procurement, and Manufacturing, with clean regulatory filings across FDA, EMA, PMDA, and SwissMedic.
Accenture · Advanced Therapies
CDMO Go-to-Market Strategy for an Automated Cell Therapy Platform
A platform technology company with an automated Level 3 cell therapy manufacturing process needed to enter the CDMO market with no established positioning or partner framework. I conducted structured interviews and surveys with pharma companies and CDMOs, then synthesised the findings into a CDMO-pharma partnership value framework covering barriers, enablers, and what each party looks for in a strategic partner. This delivered market entry positioning and a thought-leadership framework used to guide commercial strategy and partner conversations.
Johnson & Johnson · Advanced Therapies
Supply Chain Integration into Process Design
Supply chain and procurement had no visibility into pipeline process design decisions. BOM choices, material specifications, and supplier selections were being made by R&D without commercial input. I led a pilot to integrate procurement upstream, reviewing the BOM alongside the process design team before specifications were locked. Material substitutions were identified and implemented, reducing single-source dependency and improving the supply network cost position.
Accenture · Life Sciences
Supply Chain Operating Model Design and Transition
A major pharma organisation redesigning its global supply chain function needed two workstreams consolidated into a single global hub. I owned the end-to-end workstream design, transition planning, governance structure, and cut-over sequencing for both functions. Over 100 people affected. Both workstreams successfully transitioned with governance embedded and hub operations running at handover.